ClinicalTrialsFinder
RecruitingPhase 1NCT05277753

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

NGS-MRD Evaluation of Antigen-specific T Cells and DC Vaccine Combination Targeting T-cell Acute Lymphoblastic Leukemia

Sponsor

Shenzhen Geno-Immune Medical Institute

Enrollment

10 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

T-cell Acute Lymphoblastic Leukemia

Summary

The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of T-cell acute lymphoblastic leukemia (T-ALL): multi-antigen-targeted chimeric antigen receptor T cells (CAR-T) followed by engineered immune effector cytotoxic T cells (CTLs) and immune modified dendritic cell vaccine (DCvac). This approach is aimed to achieve NGS MRD negativity in T-ALL patients, which can identify a very low risk of relapse and define patients with possible long-term remission without further treatment.

Eligibility

Min Age: 6 MonthsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Antigen-specific T cells CAR-T/CTL and DCvac for people with t-cell acute lymphoblastic leukemia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 6 Months to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAntigen-specific T cells CAR-T/CTL and DCvac

Antigen-specific T cells CAR-T/CTL and DCvac cells to treat T-ALL

Locations(1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05277753

Related Trials

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

NCT065610741 location

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

NCT052896871 location

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

NCT063903194 locations

Universal 4SCAR7U Targeting CD7-positive Malignancies

NCT059950281 location

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

NCT040333021 location